Guillem Sirera

Summary

Affiliation: Hospital Universitari Germans Trias i Pujol
Country: Spain

Publications

  1. ncbi [Contribution of human papillomavirus second-generation hybrid capture test for the diagnosis of cervical pathology in HIV-infected outpatients]
    Guillem Sirera
    Unidad VIH, Servicio de Medicina, Hospital Universitario Germans Trias i Pujol, Universitat Autonoma de Barcelona, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
    Med Clin (Barc) 125:127-31. 2005
  2. ncbi Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response
    Daniel Fuster
    HIV Clinical Unit Fundació de Lluita contra la SIDA Internal Medicine Service University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    Antivir Ther 11:473-82. 2006
  3. ncbi Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients
    Cristina Tural
    HIV Clinical Unit, Internal Medicine Department, Fundació de la Lluita contra la SIDA, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 13:1047-55. 2008
  4. ncbi Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3
    Guillem Sirera
    HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona U A B, Badalona, Barcelona, Spain
    J Antimicrob Chemother 61:191-4. 2008
  5. ncbi Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment
    Ricard Sola
    Liver Section, Hospital del Mar, Institut Municipal d Investigacio Medica, Universitat Autonoma de Barcelona, 08003 Barcelona, Spain
    AIDS Res Hum Retroviruses 22:393-400. 2006
  6. ncbi Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects
    Jose Molto
    HIV Clinical Unit Lluita Contra Ia Sida Foundation, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 20:1283-8. 2004
  7. ncbi Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy
    Daniel Fuster
    HIV Clinical Unit Fundació de la Lluita contra la SIDA Internal Medicine Service and Hepatology Unit, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    Antivir Ther 10:841-7. 2005
  8. ncbi Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy
    Daniel Fuster
    HIV Clinical Unit Department, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona UAB, 08916 Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 20:1293-7. 2004
  9. doi Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus
    Cristina Tural
    HIV Clinical Unit, Fundació de la Lluita contra la SIDA, Barcelona, Spain
    Clin Gastroenterol Hepatol 7:339-45. 2009
  10. ncbi Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study
    Lidia Ruiz
    Retrovirology Laboratory, IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Infect Dis 188:977-85. 2003

Collaborators

Detail Information

Publications30

  1. ncbi [Contribution of human papillomavirus second-generation hybrid capture test for the diagnosis of cervical pathology in HIV-infected outpatients]
    Guillem Sirera
    Unidad VIH, Servicio de Medicina, Hospital Universitario Germans Trias i Pujol, Universitat Autonoma de Barcelona, Ctra de Canyet s n, 08916 Badalona, Barcelona, Spain
    Med Clin (Barc) 125:127-31. 2005
    ....
  2. ncbi Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response
    Daniel Fuster
    HIV Clinical Unit Fundació de Lluita contra la SIDA Internal Medicine Service University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Spain
    Antivir Ther 11:473-82. 2006
    ..To assess the efficacy and safety of an extended treatment period in HIV/hepatitis C virus (HCV)-coinfected patients without early virological response (EVR)...
  3. ncbi Differences in virological response to pegylated interferon and ribavirin between hepatitis C virus (HCV)-monoinfected and HCV-HIV-coinfected patients
    Cristina Tural
    HIV Clinical Unit, Internal Medicine Department, Fundació de la Lluita contra la SIDA, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    Antivir Ther 13:1047-55. 2008
    ..Suboptimal doses of ribavirin have been suggested to explain the diminished efficacy of pegylated interferon (PEG-IFN) plus ribavirin in hepatitis C virus (HCV)-HIV-coinfected patients...
  4. ncbi Highly active antiretroviral therapy and incidence of cervical squamous intraepithelial lesions among HIV-infected women with normal cytology and CD4 counts above 350 cells/mm3
    Guillem Sirera
    HIV Clinical Unit, Department of Medicine, University Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona U A B, Badalona, Barcelona, Spain
    J Antimicrob Chemother 61:191-4. 2008
    ....
  5. ncbi Poor response to hepatitis C virus (HCV) therapy in HIV- and HCV-coinfected patients is not due to lower adherence to treatment
    Ricard Sola
    Liver Section, Hospital del Mar, Institut Municipal d Investigacio Medica, Universitat Autonoma de Barcelona, 08003 Barcelona, Spain
    AIDS Res Hum Retroviruses 22:393-400. 2006
    ..In addition to improved adherence, in coinfected patients more aggressive therapeutic strategies may be necessary to achieve SVR...
  6. ncbi Influence of prior structured treatment interruptions on the length of time without antiretroviral treatment in chronically HIV-infected subjects
    Jose Molto
    HIV Clinical Unit Lluita Contra Ia Sida Foundation, Hospital Universitari Germans Trias i Pujol, 08916 Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 20:1283-8. 2004
    ..Previous STIs do not influence time off therapy when HAART is definitively discontinued in chronically HIV-infected subjects. CD4 nadir is an important factor in the treatment discontinuation decision...
  7. ncbi Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy
    Daniel Fuster
    HIV Clinical Unit Fundació de la Lluita contra la SIDA Internal Medicine Service and Hepatology Unit, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Spain
    Antivir Ther 10:841-7. 2005
    ..To assess the baseline factors associated with haematological toxicity that lead to ribavirin or pegylated interferon (peginterferon) dosage reductions in hepatitis C and human immunodeficiency virus (HCV/HIV)-coinfected patients...
  8. ncbi Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviral therapy
    Daniel Fuster
    HIV Clinical Unit Department, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona UAB, 08916 Badalona, Barcelona, Spain
    AIDS Res Hum Retroviruses 20:1293-7. 2004
    ..HIV infection is associated with advanced liver fibrosis. HIV/HCV-coinfected individuals on HAART are at risk of developing end-stage liver disease despite virological success and immunological reconstitution...
  9. doi Accuracy of simple biochemical tests in identifying liver fibrosis in patients co-infected with human immunodeficiency virus and hepatitis C virus
    Cristina Tural
    HIV Clinical Unit, Fundació de la Lluita contra la SIDA, Barcelona, Spain
    Clin Gastroenterol Hepatol 7:339-45. 2009
    ..We assessed the ability of 3 simple biochemical tests to stage liver fibrosis in patients co-infected with human immunodeficiency virus (HIV) and hepatitis C virus (HCV)...
  10. ncbi Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: the Retrogene Study
    Lidia Ruiz
    Retrovirology Laboratory, IrsiCaixa Foundation and Lluita contra la SIDA Foundation, Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    J Infect Dis 188:977-85. 2003
    ..66; 95% confidence interval, 0.47-0.93; P=.021). A prior STI seems to confer no additional benefit to subsequent virological or immunological outcomes of a salvage regimen...
  11. ncbi Long-term neuropsychiatric disorders on efavirenz-based approaches: quality of life, psychologic issues, and adherence
    Carmina R Fumaz
    Lluita contra la SIDA Foundation, HIV Unit Germans Trias i Pujol Hospital, Autonomous University of Barcelona, Barcelona, Spain
    J Acquir Immune Defic Syndr 38:560-5. 2005
    ..Efavirenz has been associated with neuropsychiatric disorders, although little is known about its long-term toxicity...
  12. doi Natural history of human papillomavirus infections involving anal, penile, and oral sites among HIV-positive men
    Sebastian Videla
    Lluita contra la SIDA Foundation, Barcelona, Spain
    Sex Transm Dis 40:3-10. 2013
    ..The aim of this study was to characterize the natural history of human papillomavirus (HPV) infection at anal canal, penile, and oral sites in HIV-positive men based on their sexual behavior...
  13. pmc Evaluation of an array-based method for human papillomavirus detection and genotyping in comparison with conventional methods used in cervical cancer screening
    Nerea García-Sierra
    Microbiology Service, Hospital Universitari Germans Trias i Pujol, Microbiology Department, Universitat Autonoma de Barcelona, Badalona, Spain
    J Clin Microbiol 47:2165-9. 2009
    ..The array method also made allowed us to determine the possible contribution of the available vaccines in our setting...
  14. pmc Randomised study to assess the efficacy and safety of once-daily etravirine-based regimen as a switching strategy in HIV-infected patients receiving a protease inhibitor-containing regimen. Etraswitch study
    Patricia Echeverria
    Department of HIV, Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Autonomous University of Barcelona, Barcelona, Spain
    PLoS ONE 9:e84676. 2014
    ..It has also shown antiviral efficacy in antiretroviral-naïve patients. However, data on the switching from protease inhibitors (PI) to ETR are lacking...
  15. ncbi Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine
    Eugenia Negredo
    Lluita contra la SIDA Foundation, Germans Trias i Pujol University Hospital, Universitat Autonoma de Barcelona, Badalona, Spain
    AIDS 16:1383-9. 2002
    ..Treatment simplification approaches in which PI are replaced by nevirapine (NVP) have been shown to improve PI-related toxicity...
  16. pmc Prevalence of ischemic heart disease and management of coronary risk in daily clinical practice: results from a Mediterranean cohort of HIV-infected patients
    Patricia Echeverria
    Lluita contra la SIDA Foundation, Hospital Universitari Germans Trias i Pujol, Badalona, 08916 Barcelona, Spain Universitat Autònoma de Barcelona, Barcelona, Spain
    Biomed Res Int 2014:823058. 2014
    ..There are conflicting data on the prevalence of coronary events and the quality of the management of modifiable cardiovascular risk factors (CVRF) in HIV-infected patients...
  17. ncbi Early HCV dynamics on Peg-interferon and ribavirin in HIV/HCV co-infection: indications for the investigation of new treatment approaches
    Angel Luis Ballesteros
    HIV Clinical Unit, University Hospital Germans Trias i Pujol, Universitat Autonoma de Barcelona, Barcelona, Spain
    AIDS 18:59-66. 2004
    ..To investigate the baseline mutations in the interferon sensitivity determining region (ISDR)2209-2248 in the non-structural 5A protein of HCV according to genotype...
  18. doi [Lymphogranuloma venereum proctocolitis in men with HIV-1 infection]
    Eva Heras
    Servicio de Medicina Interna, Hospital Universitari Germans Trias i Pujol, Universitat Autonoma de Barcelona, Badalona, Barcelona, Espana
    Enferm Infecc Microbiol Clin 29:124-6. 2011
    ..We present a series of 15 cases with lymphogranuloma venereum (LGV) with the aim of evaluating the response to a 21-day oral course of doxycycline (100mg twice daily)...
  19. ncbi Quality of life, emotional status, and adherence of HIV-1-infected patients treated with efavirenz versus protease inhibitor-containing regimens
    Carmina R Fumaz
    HIV Unit, Fundació Lluita SIDA and IrsiCaixa Retrovirology Laboratory, Germans Trias i Pujol University Hospital, Badalona, Catalonia, Spain
    J Acquir Immune Defic Syndr 29:244-53. 2002
    ....
  20. ncbi Severe interaction between ritonavir and acenocoumarol
    Josep M Llibre
    Internal Medicine Department, Hospital Sant Jaume, Barcelona, Spain
    Ann Pharmacother 36:621-3. 2002
    ..To report a clinically severe interaction between ritonavir (RTV) and acenocoumarol resulting in a decrease in the anticoagulant effect severe enough to eventually preclude RTV administration...
  21. ncbi Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression
    Eugenia Negredo
    Fundació Lluita contra la Sida, Hospital Universitari Germans Trias i Pujol, Barcelona, Spain
    Clin Infect Dis 34:504-10. 2002
    ..Quality of life significantly improved for groups A and B. In patients receiving effective PI-based therapy, the replacement of the PI with either nevirapine or efavirenz is safe and virologically effective...
  22. ncbi Evolution of cervical cytologic changes among HIV-infected women with normal cytology in the HAART era
    Guillem Sirera
    Department of Medicine, University Hospital Germans Trias i Pujol, Badalona Barcelona 08916, Spain
    AIDS Res Hum Retroviruses 23:965-71. 2007
    ..The effect of HAART on the control of HIV replication and of immunological status (>200 CD4) through the follow-up was associated with a reduction of SIL...
  23. ncbi Efavirenz induces a striking and generalized increase of HDL-cholesterol in HIV-infected patients
    Eugenia Negredo
    AIDS 18:819-21. 2004
  24. ncbi Pegylated liposomal doxorubicin plus highly active antiretroviral therapy versus highly active antiretroviral therapy alone in HIV patients with Kaposi's sarcoma
    Luz Martin-Carbonero
    AIDS 18:1737-40. 2004
    ..After 48 weeks, better response rates were observed in the HAART plus PLD group (76% versus 20%). In HIV-infected patients with moderate-advanced KS, HAART alone may not be enough for KS response...
  25. doi Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin
    L Martin-Carbonero
    Dept of Infectious Diseases, Hospital Carlos III, Madrid, Spain
    Clin Infect Dis 47:410-7. 2008
    ..However, this tumor still represents the most common cancer in this population...
  26. ncbi Advanced stage is the most important prognostic factor for survival in patients with systemic acquired immunodeficiency syndrome-related non-Hodgkin's Lymphoma treated with CHOP and highly active antiretroviral therapy
    José Tomás Navarro
    Department of Hematology, Institut Catala d Oncologia, Hospital Germans Trias i Pujol, Badalona
    Int J Hematol 86:337-42. 2007
    ..Patients with an advanced stage had a lower OS probability in a multivariate analysis (odds ratio, 4.24; 95% CI, 1.24- 14.57). Advanced stage was the main prognostic factor predicting survival in ARL treated with CHOP and HAART...
  27. ncbi Amphotericin B lipid complex versus meglumine antimoniate in the treatment of visceral leishmaniasis in patients infected with HIV: a randomized pilot study
    Fernando Laguna
    Servicio de Enfermedades Infecciosas, Hospital Carlos III, Instituto de Salud Carlos III, C Sinesio Delgado 12, 28029 Madrid, Spain
    J Antimicrob Chemother 52:464-8. 2003
    ..0006). The efficacy of ABLC is similar to meglumine antimoniate, but the severity of toxicity in the treatment of HIV-VL is lower with ABLC...
  28. ncbi Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma
    José Tomás Navarro
    Hematology Service, Hospital Universitari Germans Trias i Pujol, Badalona, Universitat Autònoma de Barcelona Barcelona, Spain
    Leuk Lymphoma 43:1837-42. 2002
    ..0168 and P = 0.028, respectively). We conclude that HAART is an independent prognostic factor for CR attainment, OS and DFS in patients with ARL treated with CHOP. Those patients with virological response to HAART had a better survival...
  29. ncbi High prevalence of human papillomavirus infection in the anus, penis and mouth in HIV-positive men
    Guillem Sirera
    HIV Clinical Unit, Department of Medicine, and Lluita Contra La SIDA Foundation, University Hospital Germans Trias i Pujol, Badalona Barcelona 08916, Spain
    AIDS 20:1201-4. 2006
    ....
  30. pmc Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus
    Rika Draenert
    Howard Hughes Medical Institute, Massachusetts General Hospital, Harvard Medical School, Charlestown, MA 02129, USA
    J Exp Med 203:529-39. 2006
    ..These results reveal considerable concordance of adaptive cellular and humoral immune responses and HIV evolution in the same genetic environment, suggesting constraints on mutational pathways to HIV immune escape...